Ruthenium(II) and Iridium(III) Complexes as Tested Materials for New Anticancer Agents.

ABSTRACT: The oncological use of cisplatin is hindered by its severe side effects and a very important resistance problem. To overcome these problems, scientists have attempted to design new generation transition-metal anticancer complexes. In this study, we present new complexes, ruthenium(II) [(η⁶-p-cymene)RuCl(py₂CO)]PF₆ (1), iridium(III) [(η⁵-Cp)IrCl(py₂CO)]PF₆ (2), and NH₄[IrCl₄(py₂CO)]·H₂O (3), based on di-2-pyridylketone (py₂CO). The prepared complexes were characterized by FTIR, ¹H, ¹³C, ¹⁵N NMR, UV-Vis, PL and elemental analysis techniques. The single-crystal X-ray structure analysis and comparative data reveale

SUBMITTER: Masternak J 

PROVIDER: S-EPMC7475896 | biostudies-literature | 2020 Aug

REPOSITORIES: biostudies-literature